Abstract: A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
Abstract: The present invention includes compounds, compositions and methods for treating and/or preventing chlorine inhalation toxicity and/or injury in a subject subjected to chlorine inhalation.
Type:
Grant
Filed:
August 17, 2018
Date of Patent:
February 22, 2022
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
Abstract: The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor.
Type:
Grant
Filed:
September 24, 2019
Date of Patent:
January 4, 2022
Assignee:
Arena Pharmaceuticals, Inc.
Inventors:
Robert M. Jones, Sangdon Han, Lars Thoresen, Jae-Kyu Jung, Sonja Strah-Pleynet, Xiuwen Zhu, Yifeng Xiong, Dawei Yue
Abstract: Described herein are assays, methods, and devices for diagnosing/prognosing Alzheimer's disease (AD) and/or a neurodegenerative disease in a subject. The assays, methods, and/or devices described herein can be configured to detect GAS5 long-coding RNAs and/or expression thereof in a sample from a subject.
Abstract: The present invention is directed to methods of inhibiting both proliferation and survival of cancer cells and for treating a subject having cancer. The present invention is further directed to methods of diagnosing cancer in a subject and identifying cancer therapeutics.
Type:
Grant
Filed:
May 25, 2018
Date of Patent:
December 28, 2021
Assignee:
NEW YORK UNIVERSITY
Inventors:
Dafna Bar-Sagi, Cosimo Commisso, Rengin De Chey
Abstract: A method and composition for extending the lifespan of an individual and delaying the onset of age-related disease is provided. The method includes the administration of an effective dose of oxaloacetate, wherein the oxaloacetate acts to mimic the cellular conditions obtained under caloric restriction to provide similar benefits. The invention further includes methods and compositions for reducing the incidence or treatment of cancer. Compositions and methods for reducing body fat by administering an effective amount of oxaloacetate are likewise provided. Compositions for DNA repair in UV damaged cells is provided are also provided. Similarly, a method for treating a hang-over comprising administering an effective amount of oxaloacetate is disclosed.
Abstract: The use of specific active substances, alone or in combination, for controlling virus infections in plants and a method for using said specific active substances for controlling said virus infections in the field of plant protection and the protection of materials are disclosed.
Type:
Grant
Filed:
January 12, 2017
Date of Patent:
November 2, 2021
Assignee:
Bayer CropScience Aktiengesellschaft
Inventors:
Rachel Baltz, David Bernier, Florence Jay-Brioudes, Thomas Knobloch, Maxime Vitel, Olivier Voinnet
Abstract: An organic amine ester derivative drug of 2-(?-hydroxypentyl)benzoic acid and a preparation method thereof and an use thereof are disclosed. The present disclosure particularly relates to a compound having the general formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable formulation prepared from the compound or the pharmaceutically acceptable salt thereof. The compound having the general formula I or the pharmaceutically acceptable salt thereof has in vitro a good solubility and a low hygroscopicity, and has in vivo a bioavailability and a brain aggregation concentration that are significantly greater than those of the original medicine butyphthalide and/or an improving drug efficacy. The use of the compound in the preparation of a drug for preventing and/or treating heart and cerebral ischemic diseases, a drug for preventing and/or treating heart and cerebral artery occlusion diseases, an anti-parkinsonian drug and an anti-senile-dementia drug is also disclosed.
Abstract: It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by malignant pediatric tumor cells. The alkylphophocholine analogs are compounds having the formula: or salts thereof, wherein n is an integer from 12 to 24; and R2 is —N+(CH3)3. The compounds can be used to treat pediatric solid tumors or to detect pediatric solid tumors. In therapeutic treatment, R1 includes a radioactive iodine isotope that locally delivers therapeutic dosages of radiation to the malignant pediatric tumor cells that preferentially take up the compound. In detection/imaging applications, R1 includes a detection moiety, such as a fluorophore or a radioactive iodine isotope.
Type:
Grant
Filed:
July 12, 2017
Date of Patent:
October 19, 2021
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Mario Otto, Dana C. Baiu, Bryan P. Bednarz, Jamey Paul Weichert
Abstract: The present disclosure provides a combination of a fused bicyclic amine compound and an anti-inflammatory agent for treating ocular inflammatory disorders and diseases. Further provided are pharmaceutical compositions of the compound and the anti-inflammatory agent.
Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.
Abstract: Novel pharmaceutical formulations of a beta-2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
Type:
Grant
Filed:
February 26, 2009
Date of Patent:
September 14, 2021
Assignee:
Glaxo Group Limited
Inventors:
Darrell Baker, Mark Bruce, Marian Thomas
Abstract: This invention applies to the field of medicine, namely to endocrinology, and intended for the treatment of type 1 diabetes mellitus. The invention proposes a combination, containing a Dipeptidyl peptidase-4 (DPP-4) inhibitors, a proton pump inhibitors (PPI), and gamma-aminobutyric acid or a gamma-aminobutyric acid receptor agonists. This unique combination of medications and specific dosage of drugs leads to the regeneration (recovery) of the ?-cells of the pancreas, which is presented by a dramatic reduction of insulin requirements up to a total insulin discontinuation in some persons.
Abstract: The present invention relates to the use of enfumafungin derivative triterpenoid antifungal compounds in combination with other antifungal agents such azoles, polyenes, lipopeptides, and allylamides to treat fungal diseases. More particularly, the invention relates to antifungal combinations of enfumafungin derivative triterpenoids which are inhibitors of (1,3)-?-D-glucan synthesis, in combination with other antifungal agents such as mold-active agents that have activity against molds, including but not limited to voriconazole, isavuconazole, posaconazole, itraconazole and amphotericin B, for the treatment and/or prevention of infections caused by molds.
Abstract: The invention provides a topical pain medication and a method of manufacturing and suing the same. In one embodiment, the medication includes: (1) enriched resveratrol having a concentration of trans-resveratrol therein that substantially exceeds the natural concentrations of trans-resveratrol in naturally occurring resveratrol, and (2) at least one inactive ingredient configured to mix with the resveratrol to form the topical medication. In one embodiment, the method includes: (1) processing resveratrol to increase the concentration of trans-resveratrol therein and (2) mixing at least one inactive ingredient with the resveratrol to form the topical medication.
Type:
Grant
Filed:
August 27, 2018
Date of Patent:
August 31, 2021
Assignee:
Ted's Brain Science, Inc.
Inventors:
Dennis I. Robbins, David H. Hitt, Jr., David H. Hitt, III
Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.
Type:
Grant
Filed:
May 20, 2016
Date of Patent:
August 24, 2021
Assignee:
AMOREPACIFIC CORPORATION
Inventors:
Byung Gyu Kim, Hyun Woo Jeong, Su Kyung Kim, Si Young Cho, Chan Woong Park, Dae Bang Seo, Wan Gi Kim, Sang Jun Lee
Abstract: The present disclosure relates to a use of a phloroglucinol-based compound and its salt for preventing and treating Alzheimer's disease. The pharmaceutical composition for preventing or treating Alzheimer's disease of the present disclosure fundamentally suppresses the cause of ?-amyloid formation, thereby exerting a remarkable effect of allowing ultimate treatment of Alzheimer's disease. The present disclosure provides the use of the single substance, which has been isolated from Dryopteris crassirhizoma and identified, for preventing or treating Alzheimer's disease for the first time.
Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.
Type:
Grant
Filed:
April 30, 2018
Date of Patent:
July 27, 2021
Inventors:
Jiann-Jyh Huang, Shih-Hsien Chuang, Ying-Shuan Eda Lee, Yu-Ling Huang, Johnson Lau